A phase II, open label, non randomized, non comparative, multi-center study to assess the efficacy and safety of olaparib given orally twice daily in patients with advanced cancers who have a confirmed genetic BRCA1 and/or BRCA2 mutation
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumor response
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation by assessment of tumor response
Assessment of objective response rate, progression free survival, overall survival, duration of response and disease control rate, safety and tolerability by collection of adverse events, hematology, clinical chemistry data, vital signs
Australia | Israel | United States
Olaparib is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.
For more information, please contact:
Cancer Study Locator service, sponsored by AstraZeneca at 1-877-400-4656 or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov
Download PDF (PDF— 
116 KB)